Italian Diagnostics company DiaSorin SpA has completed its planned $1.8bn acquisition of Luminex, the company announced 14 July.
Under the terms of the deal announced in April, DiaSorin will pay $37 a share for Luminex in an all cash deal. Funded through a mixture of cash and external...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?